Becton, Dickinson and Company (NYSE:BDX) Updates FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 12.520-12.720 for the period, compared to the consensus earnings per share estimate of 12.490. The company issued revenue guidance of -.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Friday, April 10th. They issued a “neutral” rating and a $167.00 price objective for the company. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Piper Sandler reduced their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, Barclays began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $186.57.

Becton, Dickinson and Company Stock Up 0.6%

Shares of NYSE:BDX opened at $144.99 on Thursday. The stock has a market cap of $41.28 billion, a P/E ratio of 23.65, a P/E/G ratio of 10.28 and a beta of 0.22. The firm has a fifty day moving average price of $159.08 and a 200 day moving average price of $181.33. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.52 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 1,102 shares of company stock worth $198,909. 0.40% of the stock is owned by corporate insiders.

Institutional Trading of Becton, Dickinson and Company

Hedge funds have recently made changes to their positions in the company. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $29,000. Johnson Financial Group Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $33,000. Kelleher Financial Advisors acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $37,000. Finally, Miller Capital Partners Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $43,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.